Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He has diluted this company to the point of destruction.
Read the chart? Huh, it crashed because of flawed data.
Now he wants us to forgive and forget then dilute some more.
No way man, after he does a 20:1 and its at 6.00 it will go back to .02 or even less.
My VOTE is Zero for 1 Billion shares.
I consider myself a shareholder when and if I feel like it.
This toxic mix of missed promises and flawed roll-out of research has me very nervous and hopeful at the same time.
Too many gocha's. Wish it only had 300 million in shares,
but they guy had to pay some bills. So now he thinks he can dilute himself out of his bind he is in.
Some other larger better financed company will scoop up MANF and Lympro in bankruptcy court.
Sounds good but authorizing 1 Billion more does not jive with uplisting at all. This is becoming junk paper
Really then where is the public information diversify your holdings
How about a drunken dilution party.
1 billion shares I'm going to have to protect my assets. I love the multiple uses of MANF and some of Lympro
Need to see clear numbers. If I had over a million shares I would ask myself can I sell these really or are they illiquid and worthless with another billion shares time to punch out
Think this is due by Sept
For some information. Like the improved cancer drug not perfect but helpful.
Giddi up
How is Romper Room today boys and girls.
No news ten cents
My Crystal Ball, stock goes back to .10 more shows are on,
stock goes back to .135 new news comes stock hits .20 falls back to .15 Repeat steps one and two. You'll be luck if you can sell 1 million shares without caving it in.Love the science, not so much with management.
Yes good idea but the withholding of information is getting old. Either they have something or they don't. Needs to communicate more information that is substantial. Stop the car mouse game with big Pharma.
Good luck Urano !
As long as CEO DOESNT FLUB UP AGAIN
Today's Mention in major media will have lasting impact.
14 leading companies on Alzheimer:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx Therapeutics
• Transtech Pharma
• Eli Lilly
• Amarantus BioScience Holdings, Inc
• Piramal Enterprises
• GE Healthcare
• Navidea
• Diagenic
Anybody have the link again? Its gone from the posts.
I"m not interested in increasing share count. Just executing the science we have with the employees we have. Shares can be increased on a case by case basis. An Orphan Indication filed with the FDA
and normal marketing agreement with a major distributor,
MJFox grants, anything that's coming now does not need shares.
So I"m sorry I"m not increasing my vote for more dilution.
when Orphan Announcement - .30 to .50 INMHO
Once some "big" news hits, the traders and shorters,
and na-sayers will be wiped out by a tsunami of
News Buyers who buy good news in hopes of higher highs,
and blow away the thorn in your side traders who sell this for every 1/2 a cent.
.87 up for grabs
No this is not the merger Partner. But one interesting thing,
they have some similarities.
Entered into a Purchase Agreement with Lincoln Park Capital, LLC: The Company announced in April 2014 that the Company had entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor, whereby LPC is committed to purchase up to an aggregate of $20 million of shares of the Company's common stock. Upon execution, LPC purchased 500,000 shares of common stock at $4.00 per share, for an initial investment of $2 million; the Company also issued 100,000 shares to LPC as a commitment fee for the facility. Upon the filing of the first investigational drug application for an ophthalmologic project with the U.S. Food and Drug Administration, LPC will make an additional $1 million share purchase at prevailing market prices of the Company's common stock. In addition, at the sole discretion of the Company, we may sell up to $17 million worth of common stock to LPC over the 30-month term of the agreement. The funds, in part, will serve to advance research and development activities for the Company's ophthalmological pre-clinical drug pipeline.
The vote for the 1 billion extra shares will not come to pass.
But I could see a more conservative 250 million shares.
What a joke, takes inch, then takes a foot, then takes a mile.
Amazing that this is all legal.
MANF the God Particle
Very nice Post Orion33 - excellent.
I always said, it would be nice to have MANF in a Energy Drink
This reminds me of when you get a little money from someone who owes you a lot, and you've never done business with them.
In the end you get all your money then some and your confidence is restored.
We really don't know the Commissiong's very well. They know how to pump and print and spin that we know, but can they deliver with Big Pharma? Yet to be seen. If Lympro has the numbers then let loose the dogs of war I say.
Hang in there news is coming that's a guarantee.
He Plays the Violin, the little one between your fingers.
Up UP and away AMBS on to Splitting your company into pieces to save face.
Lets add some "what if information" to this:
Looks like 45 days to blast off Or Beginning of September some news.
-- WHAT IF Near Term significant value to LymPro occurs
The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter;
-- WHAT IF - after the 12 week Study a J&J partnership occurs
with J&J or Similar company takes a 50 million Stake in Company.
We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro);
-- WHAT IF the CLIA goes off Perfectly at "J&J or similiar" lab.
We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward.
WHAT IF - New Clinical Trials begin for Eltoprazine,
We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID);
- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/#sthash.Ym1y95c1.dpuf
Looks like 45 days to blast off
The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter;
We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro);
We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward.
We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID);
- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/#sthash.Ym1y95c1.dpuf
Great time to add when its quiet time in romper room.
The most intriguing thing to happen to this company recently is the
Top Secret Capability mentioned by CEO
http://finance.yahoo.com/news/amarantus-enters-research-collaboration-buck-120000439.html
"The Company has also received a right to use certain undisclosed scientific findings for the purpose of regulatory submissions and grant applications to obtain further funding for its programs."
End Quote.
Now that initself is worth about 100million in market cap.
This could be a surprise announcement for CLIA cert with the name of the Partner:
We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward. - See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/#sthash.LrDl4Ew2.dpuf
NOTE This would in my opinion have to have a "Pre-Release" of who what when where as they Initiate the Certification process.
Even if Revenue is 20 million first year, its a start on to $500,000,000 in five years.
Every product has a starting amount even a iphone.
What was all the Talk about Spinoff Diagnostics.
It seemed in GC's Blog he is considering spinning off the Diagnostics division.
Yes Correct Orphan Status is Huge for any bio-tech. It will bring price to a future revenue point. Which in our case is 500,000,000. Market cap about 5 times higher than we are now.
The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter; We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward. We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro); We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID); - See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/#sthash.zJito9IY.dpuf
Cry 'Havoc!', and let slip the dogs of war
Reference:
http://en.wikipedia.org/wiki/The_dogs_of_war_(phrase)
Go AMBS
Thank you GC Gerald, you did it.
You released the Dogs of War on this stock.
All shareholders deserve it including management.
Let the Dogs of War thrive
There comes a day when AMBS goes up .25 cents a day.
We are approaching that apex of a leg that blows away technicals.
MANF is too powerful. Its like the Super Moon something rare and special.
With the Reverse, no change in your ownership percentage.
if you own %1.00 of company now about 7,000,000 shares
you will still own %1.00. Only difference its not on Penny OTC board will be placed on Nasdaq in future.
Its all a ways off, so the penny stock can easily float to new highs during this period of regeneration and vitalization.
Say it gets to .35 cents and more news comes out etc. JV or something its just going to RS at a higher level like $5.00 - $6.00
so the rush is on at .11cents it could easily get into the 200 million market cap level about three times higher and still have room to run and then get listed on Nasdaq with more good news the longs will be in good shape for the long haul.
OUTSTANDING just OUTSTANDING News in the last 24 hours.
Should be in the 150 to 200 million market cap area.
This is KABOOM for real .25-.35
Yes indeed it's show time Gerald
More than Copenhagen, more than United Nations debacle. It's time to release the Dogs of War.
This is where Leadership is Needed badly on Monday.
The amount of brain power the shareholders have exceeds
all the directors and consultants at AMBS. Hopefully some of the ideas and concepts discussed herein will assist them.
The news on Monday in the Blog, and the real news release needs to be very substantive and not a Re-tweet or re-post of old news.
I have seen this company re-regurgitate its old news over and over,
it is NOW TIME to SHOW the Cards. I CALL AMBS on the POKER RUN.
ORPHAN Status Rules
With MANF, being a healing protien/molecule
the number of ORPHAN drug status is in the dozens.
How does a .10 cent ten cent company uplist to NASDAQ or New York
while asking the market for another billion shares.
I was a believer in the company when it had 300 million shares.
Then the CEO an ex Football player, took this company into the
specter of dilution to a point of some type of rip off, or criminal dilution.
Yes it might look like a trick to some of you,
but in Penny land if they can pony up some big shares like that they must might pull off one of the biggest deals in penny land getting a nice fat check from Johnson and Johnson and partnering for many decades to come. Stock is their currency and they have a lot of it to splash around.
Its pretty simple if you don't own the stock then just forget it.
If you own and are nervous get a dog.
Stock price is going much higher based on all known facts.
I would give 500,000,000 to Johnson & Johnson
just as down payment and they give us about 50 million in cash.
Sounds fair to me.